Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence

@article{Reed2018RepeatedAO,
  title={Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence},
  author={Brian Reed and Eduardo R Butelman and Rebecca S Fry and Rachel Wangari Kimani and Mary Jeanne Kreek},
  journal={Neuropsychopharmacology},
  year={2018},
  volume={43},
  pages={739 - 750}
}
The κ-opioid receptor (KOP-r) system and its endogenous ligands, the dynorphins, are involved in the neurobiological regulation of addictive states, and of mood. There are limited data on the impact of selective KOP-r antagonism in humans on basic biobehavioral functions, or on addictive diseases and mood disorders. Previously studied selective KOP-r antagonists have unusual pharmacodynamic and pharmacokinetic properties (slow development of KOP-r selectivity, extremely long duration of action… 
Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat
TLDR
The KOPr antagonist attenuated escalated cocaine consumption in a rat model of extended access cocaine self-administration and prevented the increase in cocaine intake during re-exposure.
Profile of a short-acting κ-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice
TLDR
This study further implicates the λ-receptor system in ethologically relevant aspects of anhedonia, and confirms sexual dimorphism in some behavioral effects of novel κ-antagonists.
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders.
TLDR
While animal studies have indicated that compounds of this structural class are capable of normalizing withdrawal signs in animal models of cocaine and alcohol dependence and reducing cocaine andalcohol intake/seeking, additional studies are needed to determine the value of these second generation KOR antagonists in treating mood disorders and substance use disorders in humans.
Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).
TLDR
Orally administered CYM-53093 showed robust efficacy in antagonizing KOR agonist-induced prolactin secretion and in tail-flick analgesia in mice and exhibited a broad selectivity over a panel of off-target proteins.
Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice
TLDR
This study shows that the κ-receptor system is involved in an ethologically relevant measure of anhedonia, and that λ-selective doses of these antagonists can produce effects consistent with rapid anti-anhedonia.
Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.
TLDR
Centrally administered bombesin induces scratching and grooming in rats, the first evidence that KORs may be involved in the sensation of itch-like behaviors.
Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice
TLDR
BCHA, MCBPHA, and MCPPHA are novel differentially G-protein-biased kappa opioid receptor agonists that can be used to investigate how signaling pathways mediate kapp opioid receptor effects in vitro and in vivo and to explore the effects of candidate kappa opioids receptor-targeted pharmacotherapeutics.
Rapid-Onset Anti-Stress Effects of a Kappa-Opioid Receptor Antagonist, LY2795050, Against Immobility in an Open Space Swim Paradigm in Male and Female Mice
TLDR
These studies show that a novel KOR-antagonist can produce very rapid onset anti-immobility effects in this model of acute stress exposure, and may be of interest for medication development.
...
...

References

SHOWING 1-10 OF 56 REFERENCES
“Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats”
TLDR
It is suggested that acute blockade of KOPr by a relatively short-acting antagonist produces therapeutic-like effects selectively in rats with a history of chronic extended access cocaine self-administration.
Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats
TLDR
Depression and stress are two states during cocaine abstinence which users identify as precipitating relapse, and JDTic may have properties which attenuate both.
Involvement of dynorphin and kappa opioid receptor in yohimbine‐induced reinstatement of heroin seeking in rats
TLDR
The present experiments suggest that the stress responsive ppDyn/KOP-r system is a critical component of the neural circuitry underlying the effect of yohimbine stress on heroin seeking behavior and HPA activity.
Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050
TLDR
Brain penetration and KOR target engagement after single oral doses (0.5–25 mg) of LY2456302 are investigated in 13 healthy human subjects and a dose of 10 mg appears well suited for further clinical testing.
Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
TLDR
Results suggest dynorphin A1-13 lowers tuberoinfundibular dopaminergic tone through action at kappa- and possibly mu-opioid receptors, and may be effective in the management of cocaine addiction.
Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation
TLDR
This work used C57BL/6 wild type mice to determine the durations of antagonist action of novel κ-opioid receptor ligands and examined their efficacies for JNK1 activation compared with conventional competitive antagonists.
Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human
TLDR
The use of translational pupillometry in the context of receptor occupancy is demonstrated for the first time to identify a clinical dose of LY2456302 achieving maximal kappa opioid receptor occupancy without evidence of significant mu receptor antagonism.
Safety, tolerability, and pharmacokinetic evaluation of single‐ and multiple‐ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects
TLDR
The safety, tolerability, and pharmacokinetics of LY2456302 were investigated following single oral doses, multiple oral doses (2, 10, and 35 mg), and when co‐administered with ethanol and no evidence for an interaction between LY 2456302 and ethanol on cognitive‐motor performance was detected.
κ-Opioid Receptor Activation Modifies Dopamine Uptake in the Nucleus Accumbens and Opposes the Effects of Cocaine
TLDR
It is demonstrated that κ-opioid receptor activation modulates DA uptake in the Acb in a manner opposite to that of cocaine: repeated U- 69593 administration decreases the basal rate of DA uptake, and acute U-69593 administration transiently increases DA uptake.
...
...